Drug Safety
What To Know About Cobenfy, First New FDA-Approved Treatment For Schizophrenia in Decades
Cobenfy represents an answer to significant side effects from older antipsychotics—but long-term clinical testing on humans is lacking
Sep 30, 2024Menu
Shedding Light on the Risks
& Benefits of Medications
Shedding Light on the Risks
& Benefits of Medications 
Jessica DiGiacinto Head of Content
For more than 12 years, Jessica DiGiacinto has been dedicated to creating science-based content that gets beyond scary headlines to uncover important truths, while acknowledging that wellness is not a one-size-fits-all proposition. Her written and multimedia content covers topics such as new medications, nutrition and supplements, healthcare policy, and the role of food as medicine..
DiGiacinto’s previous roles include Senior Editor at Forbes Health, Healthline, and the Carnegie Corporation, which established her dedication to understanding the intricacies of new scholarly studies and a curiosity about the inner workings of the pharmaceutical industry and government regulatory agencies such as the FDA and CDC.
At MedShadow, DiGiacinto and her team work to deliver rigorous, unbiased, and independent journalism that people can use to make the choices that are right for them.
She received her MFA from NYU’s Tisch School of the Arts, and outside of health journalism, is a screenwriter with two optioned screenplays. She has lived in New Hampshire, Maine, Los Angeles, Boulder, Colorado and NYC, and enjoys spending time in nature, at the gym, listening to science podcasts, and experimenting with plant-based recipes, with varied success.
More from this writer:
Watch my videos:
What is unbiased drug-safety journalism worth to you?
We think it’s invaluable — and hope you agree. Our work is made possible by donations from readers like you.
What is Unbiased Drug-Safety Journalism Worth to You?
We think it’s invaluable — and hope you agree. Our journalism is made possible by donations from readers like you.
As a nonprofit, we don’t take a dime from pharmaceutical or supplement companies. That means we can report on the benefits, risks, and alternatives to prescription and over-the-counter drugs free from corporate pressure or influence.